Paid Clinical Trials Norfolk

Discover 406 paid clinical trials in Norfolk, Virginia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 406

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical PracticeA Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Recruiting

Sponsor:

Sarepta Therapeutics, Inc.

Location:

Norfolk VA, Philadelphia PA, Columbus OH, Londonshow 8 more

Code:

NCT04475926

Conditions

Limb-girdle Muscular Dystrophy

Eligibility Criteria

Sex: All

Age: 4+

Healthy Volunteers: Not accepted

Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Recruiting

PHASE1

PHASE2

Sponsor:

RayzeBio, Inc.

Location:

Norfolk VA, Philadelphia PA, New York NY, Pittsburg PAshow 18 more

Code:

NCT06590857

Conditions

Metastatic Breast Cancer

HER2-negative Breast Cancer

ER+ Breast Cancer

Advanced Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RYZ101

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Norfolk VA, Richmond VA, Greenville NC, Washington DCshow 103 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting

PHASE2

Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Location:

Norfolk VA, Chapel Hill NC, Baltimore MD, Philadelphia PAshow 34 more

Code:

NCT06297226

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Arlocabtagene Autoleucel (BMS-986393)

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Recruiting

Sponsor:

Hoffmann-La Roche

Location:

Norfolk VA, Lynchburg VA, Hagerstown MD, Florence SCshow 25 more

Code:

NCT05476926

Conditions

Neovascular Age-related Macular Degeneration

Diabetic Macular Edema

Retinal Vein Occlusion

Branch Retinal Vein Occlusion

Central Retinal Vein Occlusion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Faricimab

Port Delivery System with Ranibizumab

A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaA Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Portsmouth VA, Burke VA, Washington DC, Raleigh NCshow 62 more

Code:

NCT06502366

Conditions

Asthma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BDA MDI HFO 160/180 μg

BDA MDI HFA 160/180 μg

Placebo MDI HFA

Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Recruiting

PHASE1

PHASE2

Sponsor:

Genmab

Location:

Norfolk VA, Fairfax VA, Rockville MD, Doylestown PAshow 26 more

Code:

NCT05579366

Conditions

Platinum-Resistant Ovarian Cancer

Platinum Sensitive Ovarian Cancer (PSOC)

High Grade Epithelial Ovarian Cancer

High Grade Serous Ovarian Cancer

Primary Peritoneal Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rina-S

Carboplatin

Bevacizumab

Pembrolizumab

Prostate Active Surveillance StudyProstate Active Surveillance Study

Recruiting

Sponsor:

University of Washington

Location:

Norfolk VA, Boston MA, Atlanta GA, Ann Arbor MIshow 5 more

Code:

NCT00756665

Conditions

Prostatic Neoplasms

Eligibility Criteria

Sex: Male

Age: 21+

Healthy Volunteers: Not accepted

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisStudy to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

Recruiting

PHASE2

Sponsor:

Kowa Research Institute, Inc.

Location:

Suffolk VA, Richmond VA, Manassas VA, Morehead City NCshow 42 more

Code:

NCT05327127

Conditions

NASH

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

K-877-ER

CSG452

Placebo

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Recruiting

PHASE3

Sponsor:

Intec Pharma Ltd.

Location:

Virginia Beach VA, Charlottesville VA, Hershey PA, Summit NJshow 32 more

Code:

NCT02615873

Conditions

Parkinson's Disease

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Accordion Pill™ Carbidopa/Levodopa